Exhibit 23.1

 

Consent of Independent Registered Public Accounting Firm

 

We consent to the use of our reports dated March 6, 2023, with respect to the consolidated financial statements of Adaptimmune Therapeutics plc, and the effectiveness of internal control over financial reporting, incorporated herein by reference.

 

/s/ KPMG LLP
Reading, United Kingdom
November 30, 2023